Inflammatory Markers in Combination With Multiple Patterns of Extrarenal Extension Accurately Indicate Recurrence Risk in Patients With pT3aN0M0 Clear Cell Renal Cell Carcinoma
Cancer Reports · 2025-10 · 8 (10)
DOI: 10.1002/cnr2.70371 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, online erschienen am 18.10.2025. Verfasst von Masato Uetani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Toho University Faculty of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Recurrence, Local, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Background and Aims A clear understanding of the risk of clear cell renal cell carcinoma (ccRCC) recurrence in individual patients is essential for appropriate administration of adjuvant therapy. Notably, non‐metastatic pT3a ccRCCs are heterogeneous, and affected patients will have a different prognosis depending on the pathological definition. The present study was conducted to identify factors associated with postoperative recurrence in pT3a ccRCC cases.
Methods
We retrospectively reviewed 295 patients who underwent a radical or partial nephrectomy for RCC at our institution from 2013 to 2022 and identified 42 with pT3aN0M0 ccRCC. Preoperative clinical and pathological data, including blood parameters, were collected, and their association with recurrence‐free survival (RFS) was evaluated. The Kaplan–Meier method and uni‐ and multivariable Cox proportional hazard regression were used for statistical analysis.
Results
Univariate and subsequent multivariate analyses showed white blood cells, platelets, and mixed patterns of pT3a components as independent prognostic factors with significant relationships with RFS. Kaplan–Meier curves revealed that the presence of leukocytosis or thrombocytosis was associated with worse RFS ( p = 0.0002, p < 0.0001, respectively), while patients with a mixed pattern of pT3a components also had worse RFS as compared to those with a single pattern ( p = 0.0007). Furthermore, accuracy for prediction of RFS in pT3a ccRCC cases was improved by classification based on the number of retained factors, that is, leukocytosis, thrombocytosis, and mixed patterns of pT3a components.
Conclusions
The present findings indicate that inflammatory markers, such as leukocytes and platelets, as well as multiple patterns of extrarenal extension are factors useful for predicting RFS in patients with pT3aN0M0 ccRCC. Their combined use should aid in the selection of appropriate postoperative adjuvant therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Toho University Faculty of Medicine, Tokyo, Japan.
ORCID-Profile: Masato Uetani, Mizuki Kasahara, Hideyuki Kobayashi, Yozo Mitsui
Förderung
- JSPS KAKENHI
Zitieren
APA
Uetani, M., Yamabe, F., Hori, S., Kasahara, M., Okawa, M., Kobayashi, H., Nagao, K., Nakajima, K., & Mitsui, Y. (2025). Inflammatory Markers in Combination With Multiple Patterns of Extrarenal Extension Accurately Indicate Recurrence Risk in Patients With pT3aN0M0 Clear Cell Renal Cell Carcinoma. Cancer Reports, 8(10). https://doi.org/10.1002/cnr2.70371
Vancouver
Uetani M, Yamabe F, Hori S, Kasahara M, Okawa M, Kobayashi H, et al. Inflammatory Markers in Combination With Multiple Patterns of Extrarenal Extension Accurately Indicate Recurrence Risk in Patients With pT3aN0M0 Clear Cell Renal Cell Carcinoma. Cancer Reports. 2025;8(10). doi:10.1002/cnr2.70371
BibTeX
@article{Uetani2025,
author = {Uetani, Masato and Yamabe, Fumito and Hori, Shunsuke and Kasahara, Mizuki and Okawa, Mizuho and Kobayashi, Hideyuki and Nagao, Koichi and Nakajima, Koichi and Mitsui, Yozo},
title = {Inflammatory Markers in Combination With Multiple Patterns of Extrarenal Extension Accurately Indicate Recurrence Risk in Patients With pT3aN0M0 Clear Cell Renal Cell Carcinoma},
journal = {Cancer Reports},
year = {2025},
volume = {8},
number = {10},
doi = {10.1002/cnr2.70371}
}
EUVIMED